<!DOCTYPE html>
<html>
<head>
<meta name="viewport" content="width=device-width, initial-scale=1">

<script asyn src="https://kit.fontawesome.com/2c3e1e841c.js" crossorigin="anonymous"></script>
<link href="https://fonts.googleapis.com/css?family=Titillium+Web:400,700&display=swap" rel="stylesheet">
<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-119340815-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-119340815-1');
</script>

</head>
<style>
.tab {font-size: 1.6vmax;color:#a5a5a2;cursor: pointer;padding: 0.5vmax;}
.tabMobile {font-size: 3vmax;color:#888;line-height: 100%;}
.row {display: flex; justify-content:space-around;background-color: #fafaf7;}
.box {width:100%;text-align: center;margin-left: auto;margin-right: auto;padding-top: 13vh;}
.innerBox {min-height: 85vh;width: 100%;}
.flex {display: flex;}
.pad {padding: 1vmax;}
.ref {color:#888;font-size: 1.4vmax;font-weight: 400;padding: 1.5vmax;}

.rowF {display: flex;padding: 1vmax;border-bottom: #ddd solid 0.5px;}

.grey {background-color: #fafaf7;}
.blue {background-color: #D6EDE7;}
.pink {background-color:#fcdcd1;}
.orange {background-color: #f46a4f;}
.lemon {background-color: #f2d847;}
.blueTxt {color: #69bda7}
.orangeTxt {color:#f46a4f}

a {text-decoration: none;color: inherit;}

.mobileOnly {display: none;}
.mHead {display: none;} 

#home {font-size: 2.1vmax;text-align: center;color: #a5a5a2;}
@media only screen and (max-width:600px){
	.mobileOnly {display:flex}
	.noMobile {display: none;}
	.rowM {flex-direction: row;justify-content: center;background-color: white;}
    .row {flex-direction: column;}
	.tab {font-size: 1.9vmax;}
	.box {padding-top: 5vh;height: fit-content;}
	.innerBox {height: fit-content;min-height: fit-content;}
	.flex {flex-direction: column;}
	.tableH {padding: 1vmax;}
	.tableRow, .col1 {padding: 0.5vmax;}
	.mHead {color: white;font-weight: 700;font-size: 2vmax;display: block;}
	#home {font-size: 2.5vmax;}
}

@media only screen and (max-width:1200px){
	.box {height: fit-content;padding-top: 5vh;}
	.innerBox {height: fit-content;min-height: fit-content;}
	.tab {font-size: 1.9vmax;}
}

</style>

<body style='font-family: Titillium Web, sans-serif;'>

<!--sticky head-->
<div style="position: sticky;display: block;top: 0;
background-color: white;border-bottom: #fafaf7 solid 0.1vmax;">
<!--home tab-->
<div id="home">
	<a href="https://doi.org/10.1093/eurheartj/ehz467" target="_blank">
	<span><b>AF</b></span></a>
	<a href="SVT.html" style="float: left;" title="back to home page">
	<i class="fas fa-home"></i></span>
	</a>
	
</div>
<!--selector tab-->
<div class="row noMobile">
	<a href="#box1">
		<div class="tab">1</div>
	</a>
	<a href="#box2">
			<div class="tab">2</div>
	</a>
	<a href="#box3">
			<div class="tab">3</div>
	</a>
	<a href="#box4">
			<div class="tab">4</div>
    </a>
    <a href="#box5">
        <div class="tab">5</div>
    </a>
    <a href="#box6">
        <div class="tab">6</div>
    </a>
    
</div>

<div class="rowM mobileOnly">
		<a href="#box1">
			<div class="tabMobile">&nbsp;&nbsp;&nbsp;&bull;&nbsp;</div>
		</a>
		<a href="#box2">
				<div class="tabMobile">&bull;&nbsp;</div>
		</a>
		<a href="#box3">
				<div class="tabMobile">&bull;&nbsp;</div>
		</a>
		<a href="#box4">
				<div class="tabMobile">&bull;&nbsp;</div>
        </a>
        <a href="#box5">
            <div class="tabMobile">&bull;&nbsp;</div>
        </a>
        <a href="#box6">
            <div class="tabMobile">&bull;&nbsp;</div>
        </a>
        
</div>

</div>

<!--content-->

<!--AF Trials-->
<div id='box1' class="box">
	<div class="innerBox blue">
		
        <div style="font-size: 2.8vmax;padding:2vmax;color: #555;font-weight: 700;
                letter-spacing: 0;text-align: justify;">
			    Latest AF Trials - H2/2019
        </div>
        <div style="padding: 3vmax 2vmax;">
            <a href="https://doi.org/10.1016/S0140-6736(19)31872-0" target="_blank">
            <div style="background-color: white;padding: 1vmax 2vmax;text-align: left;font-size: 2.5vmax;line-height: 120%;">
                <b class="orangeTxt">ENTRUST-AF</b><br>
                In AF w/PCI, the edoxaban-based regimen was non-inferior for bleeding compared with the VKA-based regimen, without significant differences in ischaemic events.
            </div>
            </a>
        </div>

        <div style="padding: 3vmax 2vmax;">
            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1904143" target="_blank">
            <div style="background-color: white;padding: 1vmax 2vmax;text-align: left;font-size: 2.5vmax;line-height: 120%;">
                <b class="orangeTxt">AFIRE</b><br>
                In AF with stable CAD, Rivaroxaban monotherapy was non-inferior to Rivaroxaban + Antiplatelet Agent with less bleeding.
            </div>
            </a>
        </div>
				
	</div>
</div>

<!--MARM AF-->
<div id='box2' class="box">
	<div class="innerBox pink">
            
            <a href="http://www.onlinejacc.org/guidelines/atrial-fibrillation" target="_blank">
            <div class="orangeTxt" 
            style="font-size: 4vmax;padding: 2vmax 1vmax;
			font-weight: 700;text-align: left;align-self: center;;line-height: 100%;">
			    2019 ACC/AHA/HRS AF Focused Update
                
            </div></a>
            <div class="row pink">
			<div class="pad" style="align-self: center;text-align: center;flex: 0.6;">
				<img src="media/VHDNoacs.jpg"
				style="width:100%;">
            </div>
            <div style="align-self: center;font-size: 3vmax;flex: 0.4;text-align: left;padding: 3vmax;">
                <b>NOAC-eligible patients = NON-MARM AF.</b><br>
                MARM = Mechanical valve and Rheumatic Mitral Stenosis 
            </div>
            </div>

	</div>
</div>

<!--Sex-->
<div id='box3' class="box">
	<div class="innerBox orange">
		<a href="http://www.onlinejacc.org/guidelines/atrial-fibrillation" target="_blank">
            <div 
            style="font-size: 4vmax;padding: 2vmax 1vmax;color: #D6EDE7;
			font-weight: 700;text-align: left;align-self: center;;line-height: 100%;">
			    2019 ACC/AHA/HRS AF Focused Update
                
            </div></a>
        <div class="row orange">
            <div class="pad" style="align-self: center;text-align: center;flex: 0.6;">
                    <img src="media/Sc.png" style="width:100%;">
                    <div class="ref" style="color: #ddd;padding: 0;">
                        <a href="https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.029081" target="_blank">
                        Circulation 2018.
                        </a>
                    </div>
            </div>
            <div style="align-self: center;font-size: 3vmax;flex: 0.4;text-align: left;padding: 3vmax;color: white;">
                    Reasonable to omit OAC in CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 in men and 1 in women.
            </div>
        </div>
    
				
	</div>
</div>


<!--48hr-->
<div id='box4' class="box">
	<div class="innerBox lemon">
		<div class="row lemon">
            <div style="background:radial-gradient(white,#f1f1f1)">
                <img src="media/finCV.png" style="width:100%">
                <div class="w3-row w3-padding openSans w3-border-top" style="line-height: 110%;font-size: 2.2vmax">
                    CHA<sub>2</sub>DS<sub>2</sub>-VASc score is a strong predictor of thromboembolic events in 
                    cardioversion of acute AF performed without anticoagulation.
                </div>
                <div class="ref">
                    <a href="https://www.ajconline.org/article/S0002-9149(16)30146-1/fulltext" target="_blank">
                    Am J Cardiol 2016.
                    </a>
                </div>
            </div>
    
    
            <div style="font-size:2.4vmax">
                <ul style="line-height: 120%">
                                  
                    <li class="w3-green">
                        In AF/AFL of <b>48 hrs or unknown duration</b> undergoing cardioversion, 
                        anticoagulation is recommended regardless of CHA<sub>2</sub>DS<sub>2</sub>-VASc score.
                    </li>
                    <li class="w3-yellow">
                        In AF/AFL of <b>&lt;48 hrs with CHA<sub>2</sub>DS<sub>2</sub>-VASc>2 in men and >3 in women</b> undergoing cardioversion, anticoagulation is reasonable.
                    </li>
                    <li class="w3-orange">
                        In AF/AFL of <b>&lt;48 hrs with CHA<sub>2</sub>DS<sub>2</sub>-VASc=0 in men and =1 in women</b> undergoing cardioversion, 
                        anticoagulation vs. no anticoagulation may be considered.
                    </li>
                    <li style="background-color:#dfe6fa">
                        From Fin-CV registry, delay to cardioversion of <b>12 hours</b> from symptom onset was
                        associated with a greater risk of thromboembolic complications compared to cardioversion of 
                        &lt; 12 hours (1.1% versus 0.3%).
                        <div class="ref">
                            <a href="https://jamanetwork.com/journals/jama/fullarticle/1895235" target="_blank">
                            JAMA 2014.</a>
                        </div>     
                    </li>
                </ul>
            </div>
                
        </div>
	</div>
</div>

<!--AF ACS-->
<div id='box5' class="box">
	<div class="innerBox blue row">
			<div style="padding: 2vmax;font-size: 2vmax;align-self: center;flex: 1;text-align: left;color: #333;">
					<span style="font-size: 3vmax;font-weight: 700;" class="orangeTxt">
					Asymptomatic WPW
					</span><br>
					&bull; 1/5 will develop arrrhythmias related to accessory pathway.<br>
					&bull; Risk of VF occurred in 2 in 1000 person-years.<br>
					&bull; Consider EP study in pilots, professional drivers, or competitive athletes (I).<br>
					&bull; May consider EP study in other asymptomatic WPW (IIa). 
					
				</div>
				<div class="pad" style="align-self:center;flex: 1;">
					<img src="media/antegrade ERP of WPW.jpg" style="max-width: 100%;width: auto;max-height: 85vh;height: auto;">
					<div style="color: #555;font-size: 2vmax;text-align: center;">
					Antegrade ERP of Pathway = 300ms = not high-risk
					</div>
				</div>
	</div>
</div>

<!--weight loss-->
<div id='box6' class="box">
	<div class="innerBox row pink">
		<div style="align-self: center;flex: 1;" class="pad">
			<img src="media/R lat pw.jpg" style="max-width: 100%;width: auto;max-height: 85vh;height: auto;">
		</div>
		<div style="font-size: 2vmax;align-self: center;flex: 1;padding: 2vmax;">
			<span style="font-size: 2.5vmax;font-weight: 700;" class="orangeTxt">
			Electrical Dyssynchrony
			</span>
			esp. from right sided accessory pathways in septum or free wall may cause LV dysfunction.
			<br>
			<span style="font-weight: 700;">
			Catheter ablation</span> should therefore be considered (IIa).
		</div>
	</div>
</div>



<script>

window.onscroll = function(){
	checkWhoIsOn('box','tab','tabMobile')
}

function checkWhoIsOn(check,effect,effectM){
	var box = document.getElementsByClassName(check);
	var tab = document.getElementsByClassName(effect);
	var tabM = document.getElementsByClassName(effectM);
	let hMargin = 0.5*window.innerHeight;

	//check top of each box
	for (let i=0;i<box.length;i++){
		let boxTop = box[i].getBoundingClientRect().top;
		let boxBottom = box[i].getBoundingClientRect().bottom;
		
		if (boxTop<=hMargin && boxTop>0) {
			let n=i;
			activateTab(n);
		} else if (boxBottom>=hMargin && boxTop<0) {
			let n=i;
			activateTab(n);
		}
	}

	function activateTab(n){
		for (let j=0;j<tab.length;j++){
			tab[j].style.color = '#afafac'
			tab[j].style.fontWeight = "400"
			tabM[j].style.color = "black"
			tabM[j].style.fontWeight = "400"
		}
		tab[n].style.color = '#f46a4f'
		tabM[n].style.color = '#f46a4f'
		tab[n].style.fontWeight = "700"
		tabM[n].style.fontWeight = "700"
	}
	
}


</script>	

</body>
</html>
